SwiftDuct
Novel Endoscope for Safe and Accurate ERCP Procedures
Company Overview
Snapshot
Founded in May 2020 by Samantha Rush Soclof and Yevgeni Plotkin, SwiftDuct operates with 1–10 employees. The company has secured $800,000 in total capital across one funding round from MEDX Xelerator. In May 2024, SwiftDuct presented positive clinical study results for its SwiftGlide system, demonstrating its electrochemical navigation method's ability to improve ERCP procedures and outcomes.
Business overview
SwiftDuct Medical develops innovative technology to enhance the safety and accuracy of Endoscopic Retrograde Cholangiopancreatography (ERCP) procedures, aiming to reduce post-procedural complications. The company's core product, the SwiftDuct Navigation Kit, which includes the Swiftome™ and SwiftGlide™, provides gastroenterologists with advanced navigation capabilities for faster, easier, and safer ERCPs. SwiftDuct serves the healthcare industry, specifically targeting medical providers in the gastroenterology and surgical sectors with its medical devices and diagnostic technologies.
Strategic signal
In May 2024, SwiftDuct announced positive clinical study results for its SwiftGlide system at ESGE Days 2024. The study, conducted at Galilee Medical Center, demonstrated SwiftGlide's success in differentiating between bile and pancreatic/mixed juices using an electrochemical navigation method. This breakthrough signals a significant advancement in ERCP procedures, offering the potential for more accurate, fluoroscopy-free cannulation and reduced radiation exposure for patients and medical teams, thereby enhancing patient safety and operational efficiency for healthcare providers.
Log in to access full profile ›Company Intelligence Q&A
- What significant clinical milestone did SwiftDuct achieve recently?
- In May 2024, SwiftDuct presented positive clinical study results for its SwiftGlide system at ESGE Days 2024. The study demonstrated the system's ability to differentiate between bile and pancreatic/mixed juices, enabling more accurate ERCP procedures with minimal or no fluoroscopy.
- What is SwiftDuct's primary focus in medical technology?
- SwiftDuct focuses on developing novel endoscopic technology, specifically the SwiftDuct Navigation Kit (Swiftome™ and SwiftGlide™), to improve the safety and accuracy of Endoscopic Retrograde Cholangiopancreatography (ERCP) procedures and reduce post-procedural complications.
- Who were the founders of SwiftDuct?
- SwiftDuct was co-founded by Samantha Rush Soclof and Yevgeni Plotkin in May 2020.
- Which investor participated in SwiftDuct's funding round?
- In October 2020, MEDX Xelerator invested in SwiftDuct as part of a funding round that also included two other MedTech startups.
- What is the total capital raised by SwiftDuct?
- SwiftDuct has raised a total of $800,000 across one funding round.